特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
941638

CAR-T細胞療法市場:地域、ターゲット抗原、臨床試験/研究、企業別の世界予測

CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies

出版日: | 発行: Renub Research | ページ情報: 英文 167 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.56円
CAR-T細胞療法市場:地域、ターゲット抗原、臨床試験/研究、企業別の世界予測
出版日: 2020年06月01日
発行: Renub Research
ページ情報: 英文 167 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のCAR-T細胞療法市場は2028年には74億米ドルに達すると予測されています。同市場の主な成長要因には、成人および小児における癌の増加、癌における細胞療法調査を促進するための政策イニシアチブの増加、世界における臨床試験の増加などが挙げられます。

当レポートは世界のCAR-T細胞療法市場について調査しており、市場の成長要因や課題、世界の規制、標的抗原・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界市場

第3章 市場シェア

  • 地域別
  • 標的抗原別

第4章 標的抗原市場

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER2
  • Mesothelin (MESO)
  • EGFRvIII
  • その他

第5章 地域別CAR-T細胞療法市場

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東
  • アフリカ

第6章 世界のCAR-T細胞臨床試験/研究

  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • EGFRvIII
  • GD2
  • HER1
  • HER2
  • MESO

第7章 中国におけるCAR-T細胞臨床試験の詳細

  • 都市別
  • CD19
  • CD19以外
  • 固形腫瘍のCAR-T細胞

第8章 SWOT分析

第9章 規制

  • 米国
  • 欧州連合
  • 中国

第10章 IPO /投資/資金調達/提携

  • ベンチャーキャピタル投資
  • CAR-T企業の新規株式公開
  • CAR-T企業の戦略的提携/取引
  • CAR-T技術情報

第11章 成長要因

  • CAR-T療法のFDA承認
  • 世界におけるCAR-T細胞検査数の劇的な増加

第12章 市場の課題

  • 規制上の課題
  • 非常に高価なCAR-T治療

第13章 Novartis

第14章 Gilead Sciences (Kite Pharma)

第15章 Celgene Corporation(Juno Therapeutics)

第16章 Celyad

図表

List of Figures

  • Figure 2-1: Global - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 2-2: Global - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 3-1: Global - CAR-T Cell Therapy Regional Market Share (Percent), 2017 - 2019
  • Figure 3-2: Global - Forecast for CAR-T Cell Therapy Regional Market Share (Percent), 2020 - 2028
  • Figure 4-1: Global - CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 4-2: Global - CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-3: Global - Forecast for CD20 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-4: Global - Forecast for GD2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-5: Global - Forecast for CD22 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-6: Global - Forecast for CD30 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-7: Global - Forecast for CD33 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-8: Global - Forecast for HER2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-9: Global - Forecast for MESO Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-10: Global - Forecast for EGFRvIII Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-11: Global - Forecast for Others Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-1: North America - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-2: North America - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-3: Europe - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-4: Europe - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-5: Asia Pacific - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-6: Asia Pacific - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-7: Latin America - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-8: Latin America - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-9: Middle East - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-10: Middle East - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-11: Africa - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-12: Africa - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 7-1: China - By Cities CAR-T Cells Clinical Trials (Number), 2017
  • Figure 11-1: Global - CAR-T New & Total Clinical Trials (Number), 2012-2017
  • Figure 11-2: Global - By Phase CAR-T Clinical Trials (Number), 2017
  • Figure 13-1: Novartis - Global Sales (Million US$), 2015 - 2019
  • Figure 13-2: Novartis - Forecast for Global Sales (Million US$), 2020 - 2028
  • Figure 14-1: Gilead Sciences - Global Sales (Million US$), 2017 - 2019
  • Figure 14-2: Gilead Sciences - Forecast for Global Sales (Million US$), 2020 - 2028
  • Figure 15-1: Celgene - Global Sales (Million US$), 2013 - 2019
  • Figure 15-2: Celgene - Forecast for Global Sales (Million US$), 2020 - 2028
  • Figure 16-1: Celyad - Global Sales (Million US$), 2013 - 2019
  • Figure 16-2: Celyad - Forecast for Global Sales (Million US$), 2020 - 2028

List of Tables

  • Table 3 1: Global - Current & Forecast for CAR-T Cell Therapy Targeted Antigens Market Share (Percent), 2017 - 2028
  • Table 6 1: Global - Details of CD19 CAR-T Studies, 2018
  • Table 6 2: Global - Details of CD20 CAR-T Studies, 2018
  • Table 6 3: Global - Details of CD22 CAR-T Studies, 2018
  • Table 6 4: Global - Details of CD30 CAR-T Studies, 2018
  • Table 6 5: Global - Details of CD33 CAR-T Studies, 2018
  • Table 6 6: Global - Details of EGFRvIII CAR-T Studies, 2018
  • Table 6 7: Global - Details of GD2 CAR-T Studies, 2018
  • Table 6 8: Global - Details of HER1 CAR-T Studies, 2018
  • Table 6 9: Global - Details of HER2 CAR-T Studies, 2018
  • Table 6 10: Global - Details of MESO CAR-T Studies, 2018
  • Table 7 1: China - CD19 Directed CAR-T Cells Clinical Trials, 2017
  • Table 7 2: China - Non-CD19 Directed CAR-T Cells Clinical Trials, 2017
  • Table 7 3: China - Solid Tumors CAR-T Cells Clinical Trials, 2017
  • Table 10 1: Global - Venture Capital Investments (Million US$) in CAR-T Cell Therapy, 2011 - 2017
  • Table 10 2: Global - Initial Public Offerings (Million US$) in CAR-T Cell Therapy, 2011 - 2016
  • Table 10 3: Global - CAR-T Companies Strategic Partnerships/Acquisitions, 2012-2017
  • Table 10 4: Global - Key CAR-T Technology Deals, 2012-2017
目次

For many years, the support of cancer therapy was chemotherapy, surgery and radiation therapy. However, in recent times, CAR-T cell therapy has been introduced as an incredibly supportive treatment for cancer patients. Since the introduction of chemotherapy, this treatment is one of the most significant breakthroughs. In this therapy, immune cells are collected from patients, and it is modified in the laboratory by doctors. After modification, these immune cells are infused back into the patient as they can easily recognize and kill cancer cells. These infused cells get multiplied and stay in the body as "living drugs." According to Renub Research analysis, CAR-T Cell Therapy Market is expected to be USD 7.4 Billion by the end of the year 2028.

Growth Factors for CAR-T Cell Therapy

Factors such as growing numbers of cancer in adults and children, and increasing policy initiatives to encourage cell therapy research in cancer, and increasing numbers of clinical trials worldwide are some of the main drivers for the global demand for CAR T cell therapy. The economic scenario in the CAR-T cell therapy industry is very dynamic, and key players compete with each other to gain access to major markets in the United States and Europe. Companies are seeking to secure treatment facilities to increase access for patients to their treatments.

Developments did by Companies in CAR T Cell Therapy

In 2017, a new milestone was set for oncology patients when the FDA approved the first two CD19-targeted known as (Chimeric Antigen Receptor) CAR T cell therapies produced by Novartis and Gilead Sciences known as Kite Pharma in the United States. Such two approvals have helped to improve the global demand for CAR T cell therapy because more companies are searching for this excellent opportunity to reach the marketplace. More than 200 CAR T clinical trials are ongoing or completed in various parts of the world. In 2018, Novartis announced its 33 approved centres in the U.S. and Gilead announced its 28 approved centres for the care of patients. Companies are also coming up with new developments in the field.

Celgene, a global company, is expected to file for approval in USFDA of bb2121 (idecabtagene vicleucel) in myeloma during the first half of 2020 and lisocabtagene maraleucel in lymphoma in the fourth quarter of 2020.

Renub Research latest study report "CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others), Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, MESO, EGFRvII), Companies (Novartis, Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)" provides a detailed and comprehensive insight of the global CAR T cell therapy market.

By Antigens - Based on antigens, CAR T Cell Therapy Market is further Segmented into 10 Segments

  • 1. CD19
  • 2. CD20
  • 3. GD2
  • 4. CD22
  • 5. CD30
  • 6. CD33
  • 7. HER2
  • 8. MESO
  • 9. EGFRvII
  • 10. Others

By Region - 6 Regions CAR T Cell Market is studied in this report

  • 1. North America
  • 2. Europe
  • 3. Asia Pacific
  • 4. Latin America
  • 5. Middle East
  • 6. Africa

All the companies have been studied from three points

  • Overview
  • Initiatives & Recent Developments
  • Revenue

Key Companies covered in this report are

  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad

Global - CAR T Cell Therapy Clinical Trials/Study

  • 1. CD19
  • 2. CD20
  • 3. GD2
  • 4. CD22
  • 5. CD30
  • 6. CD33
  • 7. HER1
  • 8. HER2
  • 9. MESO
  • 10. EGFRvII

China CAR T Cells Clinical Trials Details

  • By Cities CAR T Cells Clinical Trials
  • CD19 Directed CAR T Cells Clinical Trials
  • Non-CD19 Directed CAR T Cells Clinical Trials
  • Solid Tumors CAR T Cells Clinical Trials

Regulation of CAR T Cell Therapy in 3 Regions is covered in the report

  • United States
  • European Union
  • China

IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

  • Venture Capital Investment
  • Initial Public Offerings
  • Strategic Partnerships/Deals
  • Key CAR T Technology Deals

Table of Contents

1. Executive Summary

2. Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market

3. Market Share - CAR-T Cell Therapy

  • 3.1 By Geographical Region
  • 3.2 By Targeted Antigens

4. Targeted Antigen Market

  • 4.1 CD19
    • 4.1.1 Introduction
    • 4.1.2 Market Size and Forecast
  • 4.2 CD20
    • 4.2.1 Introduction
    • 4.2.2 Market Size and Forecast
  • 4.3 GD2
    • 4.3.1 Introduction
    • 4.3.2 Market Size and Forecast
  • 4.4 CD22
    • 4.4.1 Introduction
    • 4.4.2 Market Size and Forecast
  • 4.5 CD30
    • 4.5.1 Introduction
    • 4.5.2 Market Size and Forecast
  • 4.6 CD33
    • 4.6.1 Introduction
    • 4.6.2 Market Size and Forecast
  • 4.7 HER2
    • 4.7.1 Introduction
    • 4.7.2 Market Size and Forecast
  • 4.8 Mesothelin (MESO)
    • 4.8.1 Introduction
    • 4.8.2 Market Size and Forecast
  • 4.9 EGFRvIII
    • 4.9.1 Introduction
    • 4.9.2 Market Size and Forecast
  • 4.10 Others
    • 4.10.1 Market Size and Forecast

5. Geographical CAR-T Cell Therapy Market (2016 -2026)

  • 5.1 North America
  • 5.2 Europe
  • 5.3 Asia Pacific
  • 5.4 Latin America
  • 5.5 Middle East
  • 5.6 Africa

6. Global - CAR-T Cell Clinical Trials/Study

  • 6.1 CD19
  • 6.2 CD20
  • 6.3 CD22
  • 6.4 CD30
  • 6.5 CD33
  • 6.6 EGFRvIII
  • 6.7 GD2
  • 6.8 HER1
  • 6.9 HER2
  • 6.10 MESO

7. China CAR-T Cells Clinical Trials Details

  • 7.1 By Cities CAR-T Cells Clinical Trials
  • 7.2 CD19 Directed CAR-T Cells Clinical Trials
  • 7.3 Non-CD19 Directed CAR-T Cells Clinical Trials
  • 7.4 Solid Tumors CAR-T Cells Clinical Trials

8. CAR-T Cell Therapy SWOT Analysis

  • 8.1 Strength
  • 8.2 Weakness
  • 8.3 Opportunities
  • 8.4 Threats

9. Regulation in CAR-T Cell Therapy

  • 9.1 United States
  • 9.2 European Union
  • 9.3 China

10. IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

  • 10.1 Venture Capital Investment
  • 10.2 Initial Public Offerings of CAR-T Companies
  • 10.3 CAR-T Companies Strategic Partnerships/Deals
  • 10.4 Key CAR-T Technology Deals

11. Growth Drivers

  • 11.1 FDA Approvals of CAR-T Therapy
  • 11.2 Dramatically Increasing Number of CAR-T Cell Trials Globally

12. Challenges

  • 12.1 Regulatory Challenges
  • 12.2 Very Expensive CAR-T Therapy Treatment

13. Novartis

  • 13.1 Company Overview
  • 13.2 Initiatives
    • 13.2.1 Point 1
    • 13.2.2 Point 2 Kymriah® (tisagenlecleucel), First-in-class CAR-T Therapy from Novartis Received Second FDA Approval
    • 13.2.3 Point 2
  • 13.3 Financial Insight

14. Gilead Sciences (Kite Pharma)

  • 14.1 Company Overview
  • 14.2 Company Initiatives
    • 14.2.1 Point 1
    • 14.2.2 Point 2
  • 14.3 Company Financial Insight

15. Celgene Corporation (Juno Therapeutics)

  • 15.1 Company Overview
  • 15.2 Company Initiatives
    • 15.2.1 Point 1
    • 15.2.2 Point 2
  • 15.3 Company Financial Insight

16. Celyad

  • 16.1 Company Overview
  • 16.2 Company Initiatives
    • 16.2.1 Point 1
    • 16.2.2 Point 2
    • 16.2.3 Point 3
  • 16.3 Financial Insight
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.